These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28066999)

  • 21. Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs.
    Mabilangan C; Burton C; Nahirniak S; O'Brien S; Preiksaitis J
    Am J Transplant; 2020 Dec; 20(12):3509-3519. PubMed ID: 32428296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New blood-borne virus infections among organ transplant recipients: An Australian data-linked cohort study examining donor transmissions and other HIV, hepatitis C and hepatitis B notifications, 2000-2015.
    Waller KMJ; De La Mata NL; Hedley JA; Rosales BM; O'Leary MJ; Cavazzoni E; Ramachandran V; Rawlinson WD; Kelly PJ; Wyburn KR; Webster AC
    Transpl Infect Dis; 2020 Dec; 22(6):e13437. PubMed ID: 32767859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.
    Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
    Transplantation; 2015 Mar; 99(3):602-8. PubMed ID: 25148381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR National Registry Data in the United States.
    Dharnidharka VR; Lamb KE; Gregg JA; Meier-Kriesche HU
    Am J Transplant; 2012 Apr; 12(4):976-83. PubMed ID: 22226225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
    Geris JM; Spector LG; Pfeiffer RM; Limaye AP; Yu KJ; Engels EA
    Cancer; 2022 Nov; 128(22):3985-3994. PubMed ID: 36126024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valganciclovir administration to kidney donors to reduce the burden of cytomegalovirus and Epstein-Barr virus transmission during transplantation.
    Verghese PS; Schmeling DO; Knight JA; Matas AJ; Balfour HH
    Transplantation; 2015 Jun; 99(6):1186-91. PubMed ID: 25489844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R; Comoli P; Caillard S; Moulin B; Hirsch HH; Meylan P;
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients.
    Lazda VA
    Transplant Proc; 2006 Dec; 38(10):3404-5. PubMed ID: 17175286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients.
    Ison MG; Llata E; Conover CS; Friedewald JJ; Gerber SI; Grigoryan A; Heneine W; Millis JM; Simon DM; Teo CG; Kuehnert MJ;
    Am J Transplant; 2011 Jun; 11(6):1218-25. PubMed ID: 21645254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients.
    Yazawa M; Fülöp T; Cseprekal O; Talwar M; Balaraman V; Bhalla A; Azhar A; Kovesdy CP; Eason JD; Molnar MZ
    Ren Fail; 2020 Nov; 42(1):1083-1092. PubMed ID: 33100098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying the patient at risk for post-transplant lymphoproliferative disorder.
    Cockfield SM
    Transpl Infect Dis; 2001 Jun; 3(2):70-8. PubMed ID: 11395972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey.
    Khedmat H; Taheri S
    Exp Clin Transplant; 2012 Apr; 10(2):141-7. PubMed ID: 22432758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H; Oschlies I; Fink S; Pott C; Neumayer HH; Lehmkuhl H; Hauser IA; Dreyling M; Kneba M; Gärtner B; Anagnostopoulos I; Riess H; Klapper W; Trappe RU
    Transplantation; 2012 Mar; 93(5):543-50. PubMed ID: 22234349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients.
    Shapiro NL; Tang CG; Bhattacharyya N
    Laryngoscope; 2011 Aug; 121(8):1718-25. PubMed ID: 21792960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
    Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.
    Schachtner T; Reinke P
    Transpl Infect Dis; 2016 Dec; 18(6):881-888. PubMed ID: 27632022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Malinis M; Boucher HW;
    Clin Transplant; 2019 Sep; 33(9):e13548. PubMed ID: 30900327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral prophylaxis in organ transplant patients.
    Slifkin M; Doron S; Snydman DR
    Drugs; 2004; 64(24):2763-92. PubMed ID: 15563248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.